Fidelity Investments’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-558,960
| Closed | -$71.6M | – | 5389 |
|
|
2025
Q2 | $71.6M | Sell |
558,960
-874,209
| -61% | -$90.8M | ﹤0.01% | 1256 |
|
|
2025
Q1 | $127M | Sell |
1,433,169
-814,510
| -36% | -$79.5M | 0.01% | 995 |
|
|
2024
Q4 | $196M | Sell |
2,247,679
-2,269,092
| -50% | -$208M | 0.01% | 831 |
|
|
2024
Q3 | $418M | Sell |
4,516,771
-316,913
| -7% | -$31.5M | 0.03% | 545 |
|
|
2024
Q2 | $521M | Sell |
4,833,684
-335,833
| -6% | -$33.6M | 0.03% | 433 |
|
|
2024
Q1 | $490M | Buy |
5,169,517
+821,206
| +19% | +$70.4M | 0.03% | 461 |
|
|
2023
Q4 | $401M | Sell |
4,348,311
-1,736,944
| -29% | -$113M | 0.03% | 485 |
|
|
2023
Q3 | $306M | Sell |
6,085,255
-622,882
| -9% | -$33.3M | 0.03% | 549 |
|
|
2023
Q2 | $424M | Sell |
6,708,137
-2,113,985
| -24% | -$115M | 0.04% | 461 |
|
|
2023
Q1 | $397M | Sell |
8,822,122
-152,423
| -2% | -$6.87M | 0.04% | 476 |
|
|
2022
Q4 | $393M | Buy |
8,974,545
+16,619
| +0.2% | +$797K | 0.04% | 473 |
|
|
2022
Q3 | $590M | Buy |
8,957,926
+381,847
| +4% | +$24.5M | 0.06% | 302 |
|
|
2022
Q2 | $433M | Buy |
8,576,079
+3,242,698
| +61% | +$190M | 0.04% | 418 |
|
|
2022
Q1 | $341M | Buy |
5,333,381
+2,984,929
| +127% | +$214M | 0.03% | 576 |
|
|
2021
Q4 | $252M | Sell |
2,348,452
-863,512
| -27% | -$90.3M | 0.02% | 712 |
|
|
2021
Q3 | $330M | Sell |
3,211,964
-1,038,167
| -24% | -$96.7M | 0.03% | 592 |
|
|
2021
Q2 | $374M | Sell |
4,250,131
-23,485
| -0.5% | -$2.15M | 0.03% | 561 |
|
|
2021
Q1 | $416M | Buy |
4,273,616
+83,241
| +2% | +$8.31M | 0.04% | 492 |
|
|
2020
Q4 | $470M | Buy |
4,190,375
+361,526
| +9% | +$38.1M | 0.04% | 426 |
|
|
2020
Q3 | $355M | Buy |
3,828,849
+68,308
| +2% | +$5.26M | 0.04% | 420 |
|
|
2020
Q2 | $293M | Sell |
3,760,541
-1,347,178
| -26% | -$91.1M | 0.03% | 470 |
|
|
2020
Q1 | $299M | Sell |
5,107,719
-2,271,471
| -31% | -$146M | 0.04% | 379 |
|
|
2019
Q4 | $591M | Buy |
7,379,190
+23,267
| +0.3% | +$1.74M | 0.07% | 278 |
|
|
2019
Q3 | $540M | Buy |
7,355,923
+210,685
| +3% | +$18.2M | 0.06% | 291 |
|
|
2019
Q2 | $674M | Buy |
7,145,238
+205,944
| +3% | +$17M | 0.08% | 249 |
|
|
2019
Q1 | $555M | Buy |
6,939,294
+346,738
| +5% | +$25.6M | 0.07% | 290 |
|
|
2018
Q4 | $355M | Buy |
6,592,556
+9,397
| +0.1% | +$571K | 0.05% | 380 |
|
|
2018
Q3 | $514M | Buy |
6,583,159
+7,559
| +0.1% | +$525K | 0.06% | 320 |
|
|
2018
Q2 | $417M | Buy |
6,575,600
+44,401
| +0.7% | +$3.53M | 0.05% | 370 |
|
|
2018
Q1 | $599M | Buy |
6,531,199
+100,240
| +2% | +$8.64M | 0.07% | 287 |
|
|
2017
Q4 | $485M | Buy |
6,430,959
+564,056
| +10% | +$39.7M | 0.06% | 355 |
|
|
2017
Q3 | $409M | Buy |
5,866,903
+566,314
| +11% | +$30.3M | 0.05% | 399 |
|
|
2017
Q2 | $269M | Buy |
5,300,589
+516,835
| +11% | +$21.9M | 0.03% | 560 |
|
|
2017
Q1 | $191M | Buy |
4,783,754
+905,614
| +23% | +$32.4M | 0.02% | 713 |
|
|
2016
Q4 | $109M | Sell |
3,878,140
-51,322
| -1% | -$1.55M | 0.01% | 950 |
|
|
2016
Q3 | $117M | Sell |
3,929,462
-156,138
| -4% | -$3.88M | 0.02% | 903 |
|
|
2016
Q2 | $82.7M | Buy |
4,085,600
+15,615
| +0.4% | +$284K | 0.01% | 1069 |
|
|
2016
Q1 | $73.5M | Buy |
4,069,985
+553,512
| +16% | +$9.6M | 0.01% | 1098 |
|
|
2015
Q4 | $92.6M | Sell |
3,516,473
-550,345
| -14% | -$12.4M | 0.01% | 998 |
|
|
2015
Q3 | $86.8M | Buy |
4,066,818
+108
| +0% | +$2.99K | 0.01% | 1016 |
|
|
2015
Q2 | $108M | Buy |
+4,066,710
| New | +$116M | 0.01% | 1005 |
|
Other funds holding BPMC
IA
HNB
Fidelity Investments's BPMC Position: Q3 2025 in Review
Fidelity Investments sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 558,960 shares — an estimated $71.6M sold.
Fidelity Investments first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $674M in Q2 2019. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Fidelity Investments reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Fidelity Investments sold 558,960 Blueprint Medicines shares in Q3 2025, an estimated $71.6M.
- Fidelity Investments first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- Fidelity Investments's Blueprint Medicines position peaked at $674M in Q2 2019.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.